We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.
A California-based biotech company is already stealing the show during Wednesday’s premarket after the company announced a CEO transition and an estimated 83% reduction in To read the full...
– Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim CEO – SAN MATEO, Calif. and...
– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo...
– Discontinuing development of istisociclib, a CDK9 inhibitor; benefit-risk profile in platinum-resistant high-grade serous ovarian cancer does not support further development – – Kronos Bio...
– Data demonstrates Kronos Bio's approach to targeting oncogenic transcription factors and the strong relationship between IRF4 and p300 in Multiple Myeloma – – Poster presentation to take place...
SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.08 | 8.69565217391 | 0.92 | 0.997 | 0.8902 | 443695 | 0.94470887 | CS |
4 | -0.01 | -0.990099009901 | 1.01 | 1.09 | 0.8902 | 335985 | 0.95674916 | CS |
12 | 0.06 | 6.3829787234 | 0.94 | 1.09 | 0.8 | 259318 | 0.93584368 | CS |
26 | -0.18 | -15.2542372881 | 1.18 | 1.6 | 0.8 | 181122 | 1.01580496 | CS |
52 | -0.15 | -13.0434782609 | 1.15 | 1.6 | 0.69 | 281836 | 1.042141 | CS |
156 | -12.62 | -92.657856094 | 13.62 | 14.57 | 0.69 | 295849 | 2.58031934 | CS |
260 | -27.29 | -96.4651820431 | 28.29 | 39.605 | 0.69 | 281211 | 8.16527747 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions